Literature for indinavir (A02.001 inhibitor)

(Topics flags: S Structure, I Inhibitor, V Review. To select only the references relevant to a single topic, click the link above. See explanation.)

2015

2006

Mastrolorenzo,A., Rusconi,S., Scozzafava,A. and Supuran,C.T.
Inhibitors of HIV-1 protease: 10 years after
Expert Opin Ther Pat16, 1067-1091. DOI V I

2004

[YEAR:28-9-2004]Chen,X., Weber,I.T. and Harrison,R.W.
Molecular dynamics simulations of 14 HIV protease mutants in complexes with indinavir
J Mol Model10, 373-381. PubMed Europe PubMed DOI I
[YEAR:28-9-2004]Clemente,J.C., Moose,R.E., Hemrajani,R., Whitford,L.R., Govindasamy,L., Reutzel,R., McKenna,R., Agbandje-McKenna,M., Goodenow,M.M. and Dunn,B.M.
Comparing the accumulation of active- and nonactive-site mutations in the HIV-1 protease
Biochemistry43, 12141-12151. PubMed Europe PubMed DOI S I
de Mendoza,C. and Soriano,V.
Resistance to HIV protease inhibitors: mechanisms and clinical consequences
Curr Drug Metab5, 321-328. PubMed Europe PubMed DOI I
Mahalingam,B., Wang,Y.F., Boross,P.I., Tozser,J., Louis,J.M., Harrison,R.W. and Weber,I.T.
Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site
Eur J Biochem271, 1516-1524. PubMed Europe PubMed DOI S I

2003

[YEAR:17-11-2003]Kevin,N.J., Duffy,J.L., Kirk,B.A., Chapman,K.T., Schleif,W.A., Olsen,D.B., Stahlhut,M., Rutkowski,C.A., Kuo,L.C., Jin,L., Lin,J.H., Emini,E.A. and Tata,J.R.
Novel HIV-1 protease inhibitors active against multiple PI-resistant viral strains: coadministration with indinavir
Bioorg Med Chem Lett13, 4027-4030. PubMed Europe PubMed DOI I

2002

King,N.M., Melnick,L., Prabu-Jeyabalan,M., Nalivaika,E.A., Yang,S.S., Gao,Y., Nie,X., Zepp,C., Heefner,D.L. and Schiffer,C.A.
Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease
Protein Sci11, 418-429. PubMed Europe PubMed DOI S I

2001

Qari,S.H., Magre,S., Garcia-Lerma,J.G., Hussain,A.I., Takeuchi,Y., Patience,C., Weiss,R.A. and Heneine,W.
Susceptibility of the porcine endogenous retrovirus to reverse transcriptase and protease inhibitors
J Virol75, 1048-1053. PubMed Europe PubMed DOI I

2000

[YEAR:3-10-2000]Todd,M.J., Luque,I., Velazquez-Campoy,A. and Freire,E.
Thermodynamic basis of resistance to HIV-1 protease inhibition: calorimetric analysis of the V82F/I84V active site resistant mutant
Biochemistry39, 11876-11883. PubMed Europe PubMed DOI I
[YEAR:21-9-2000]Tyndall,J.D., Reid,R.C., Tyssen,D.P., Jardine,D.K., Todd,B., Passmore,M., March,D.R., Pattenden,L.K., Bergman,D.A., Alewood,D., Hu,S.H., Alewood,P.F., Birch,C.J., Martin,J.L. and Fairlie,D.P.
Synthesis, stability, antiviral activity, and protease-bound structures of substrate-mimicking constrained macrocyclic inhibitors of HIV-1 protease
J Med Chem43, 3495-3504. PubMed Europe PubMed DOI I

1999

Korting,H.C., Schaller,M., Eder,G., Hamm,G., Bohmer,U. and Hube,B.
Effects of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-Infected patients
Antimicrobial Agents Chemother43, 2038-2042. PubMed Europe PubMed I
Monod,M., Borg-von Zepelin,M., Telenti,A. and Sanglard,D.
The inhibition of Candida-albicans-secreted aspartic proteases by three different HIV protease inhibitors
Dermatology198, 412-414. PubMed Europe PubMed I

1998

[YEAR:8-12-1998]Towler,E.M., Gulnik,S.V., Bhat,T.N., Xie,D., Gustschina,E., Sumpter,T.R., Robertson,N., Jones,C., Sauter,M., Mueller-Lantzsch,N., Debouck,C. and Erickson,J.W.
Functional characterization of the protease of human endogenous retrovirus, K10: can it complement HIV-1 protease?
Biochemistry37, 17137-17144. PubMed Europe PubMed DOI I
Wlodawer,A. and Vondrasek,J.
Inhibitors of HIV-1 protease: a major success of structure-assisted drug design
Annu Rev Biophys Biomol Struct27, 249-284. PubMed Europe PubMed DOI V I

1997

Cornelissen,M., van den Burg,R., Zorgdrager,F., Lukashov,V. and Goudsmit,J.
pol gene diversity of five human immunodeficiency virus type 1 subtypes: evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D
J Virol71, 6348-6358. PubMed Europe PubMed I
Wilson,S.I., Phylip,L.H., Mills,J.S., Gulnik,S.V., Erickson,J.W., Dunn,B.M. and Kay,J.
Escape mutants of HIV-1 proteinase: enzymic efficiency and susceptibility to inhibition
Biochim Biophys Acta1339, 113-125. PubMed Europe PubMed DOI I

1995

[YEAR:6-4-1995]Condra,J.H., Schleif,W.A., Blahy,O.M., Gabryelski,L.J., Graham,D.J., Quintero,J.C., Rhodes,A., Robbins,H.L., Roth,E. and Shivaprakash,M.
In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
Nature374, 569-571. PubMed Europe PubMed DOI I
Tisdale,M., Myers,R.E., Maschera,B., Parry,N.R., Oliver,N.M. and Blair,E.D.
Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors
Antimicrobial Agents Chemother39, 1704-1710. PubMed Europe PubMed I

1994

Chen,Z., Li,Y., Chen,E., Hall,D.L., Darke,P.L., Culberson,C., Shafer,J.A. and Kuo,L.C.
Crystal structure at 1.9-A resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases
J Biol Chem269, 26344-26348. PubMed Europe PubMed S I
[YEAR:14-10-1994]Dorsey,B.D., Levin,R.B., McDaniel,S.L., Vacca,J.P., Guare,J.P., Darke,P.L., Zugay,J.A., Emini,E.A., Schleif,W.A. and Quintero,J.C.
L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor
J Med Chem37, 3443-3451. PubMed Europe PubMed DOI I
[YEAR:26-4-1994]Vacca,J.P., Dorsey,B.D., Schleif,W.A., Levin,R.B., McDaniel,S.L., Darke,P.L., Zugay,J., Quintero,J.C., Blahy,O.M. and Roth,E.
L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor
Proc Natl Acad Sci U S A91, 4096-4100. PubMed Europe PubMed I